Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01918176 · ClinicalTrials.gov registry record · Phase 1

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

A Phase 1 study of Healthy, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
1
Study location

NCT01918176: Completed Phase 1 study of Healthy, sponsored by Pfizer.

NCT01918176 is a Phase 1 study of Healthy that has completed, run by Pfizer. The registered enrollment target is 26 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01918176, a Phase 1 study of Healthy, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

Fixed sequence, 2-period crossover study to compare the pharmacokinetic profiles of Palbociclib in absence and presence of prior administration of proton pump inhibitor Rabeprazole. The increased gastric pH achieved by the treatment with multiple doses of Rabeprazole might affect the absorption process of Palbociclib.

Primary Outcome

AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).

Conditions Studied

Interventions

  • DRUG Palbociclib alone
  • DRUG Palbociclib + Rabeprazole

Study Locations (1)

Florida

  • Pfizer Investigational Site - South Miami

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2013-09
Est. Completion 2013-12
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT01918176 record still lists

NCT01918176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Palbociclib alone is the first listed.

NCT01918176 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT01918176 about?

NCT01918176 is a clinical study titled "Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)". Fixed sequence, 2-period crossover study to compare the pharmacokinetic profiles of Palbociclib in absence and presence of prior administration of proton pump inhibitor Rabeprazole. The increased gastric pH achieved by the treatment with multiple doses of Rabeprazole might affect the absorption proc...

What is the current status of trial NCT01918176?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-09. Estimated completion is 2013-12.

What conditions does trial NCT01918176 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01918176?

The interventions under investigation include: Palbociclib alone (DRUG), Palbociclib + Rabeprazole (DRUG).

Who is sponsoring clinical trial NCT01918176?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01918176 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01918176's enrollment target sits among peer trials

26 760th of 1090 higher than 314 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01918176, the US trial registry maintained by the National Library of Medicine. NCT01918176 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.